Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Form 1 of AZD5718 · 1 trial · 1 indication
To assess the pharmacokinetics (PK) parameter AUC to evaluate the relative bioavailability of different formulations of AZD5718 and compare with the formulation (Form 1 of AZD5718 tablets) used in the Phase 2a clinical study.
To assess the PK parameter AUC(0-t)to evaluate the relative bioavailability of different formulations of AZD5718 and compare with the formulation (Form 1 of AZD5718 tablets) used in the Phase 2a clinical study.
To assess the PK parameter Cmax to evaluate the relative bioavailability of different formulations of AZD5718 and compare with the formulation (Form 1 of AZD5718 tablets) used in the Phase 2a clinical study.
To assess the PK parameter C24 to evaluate the relative bioavailability of different formulations of AZD5718 and compare with the formulation (Form 1 of AZD5718 tablets) used in the Phase 2a clinical study.
| Arm | Type | Description |
|---|---|---|
| Treatment A | EXPERIMENTAL | The participant will be administered with Form 1 of AZD5718 tablets with an overnight fast of at least 10 hours. |
| Treatment B | EXPERIMENTAL | The participant will be administered with Form 2 of AZD5718 tablets with an overnight fast of at least 10 hours. |
| Treatment C | EXPERIMENTAL | The participant will be administered with Form 3 of AZD5718 tablets with an overnight fast of at least 10 hours. |
| Treatment D | EXPERIMENTAL | The participant will be administered with Form 4 of AZD5718 tablets with an overnight fast of at least 10 hours. |
| Treatment E | EXPERIMENTAL | The participant will be administered with Form 5 of AZD5718 tablets with an overnight fast of at least 10 hours. |
| Treatment F | EXPERIMENTAL | The participant will be administered with selected form (one of Form 2-5) of AZD5718 tablets 30 minutes after start of the meal. |
| Name | Type | Description |
|---|---|---|
| Form 1 of AZD5718 tablets | DRUG | The participants will be dosed with Form 1 of AZD5718 following an overnight fast of at least 10 hours. |
| Form 2 of AZD5718 tablets | DRUG | The participants will be dosed with Form 2 of AZD5718 following an overnight fast of at least 10 hours. |
| Form 3 of AZD5718 tablets | DRUG | The participants will be dosed with Form 3 of AZD5718 following an overnight fast of at least 10 hours. |
| Form 4 of AZD5718 tablets | DRUG | The participants will be dosed with Form 4 of AZD5718 following an overnight fast of at least 10 hours. |
| Form 5 of AZD5718 tablets | DRUG | The participants will be dosed with Form 5 of AZD5718 following an overnight fast of at least 10 hours. |
| Selected form (Form 2 - 5) of AZD5718 tablets | DRUG | The participant will be administered with selected form (one of Form 2-5) of AZD5718 tablets 30 minutes after start of the meal. |
Inclusion Criteria: 1. Provision of signed and dated, written informed consent before any study specific procedures. 2. Healthy male and/or female subjects aged 18 to 55 years (inclusive) with suitable veins for cannulation or repeated venipuncture. 3. Females must have a negative pregnancy test at...
Form 1 of AZD5718 is an investigational small molecule being developed by AstraZeneca for Coronary Artery Disease. It is currently in Phase 1 clinical development, meaning it has not been approved and is still being studied for safety and tolerability in early-stage trials.
Form 1 of AZD5718 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The drug is a small molecule intended for the treatment of Coronary Artery Disease and is currently in Phase 1 clinical trials.
Form 1 of AZD5718 is in Phase 1 clinical development. It is an investigational drug, meaning it is not yet approved for use. The Phase 1 trial has been completed, and the drug is being studied for its bioavailability and food effects in healthy volunteers.
Form 1 of AZD5718 has one completed Phase 1 clinical trial, identified as NCT03420092. This study assessed the bioavailability of different formulations of AZD5718 and the food effect on the selected formulation in healthy volunteers. The trial enrolled 14 participants and was conducted in the United Kingdom.
Yes, Form 1 of AZD5718 is a specific formulation of the drug AZD5718. The clinical trial NCT03420092 was designed to compare different formulations of AZD5718, including Form 1, to evaluate their bioavailability and how food affects the selected formulation in healthy volunteers.